Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Antithymocyte globulin; Carmustine; Cytarabine; Etoposide; Filgrastim; Melphalan; Methotrexate; Rituximab; Tacrolimus; Tacrolimus
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2018 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2021.
- 21 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.